GENEPID: A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses (clinicaltrials.gov) - Oct 17, 2026 - P2 | N=8 | Completed | Sponsor: Centre Hospitalier Universitaire de Nice | Recruiting ➔ Completed | Trial primary completion date: Sep 2025 ➔ Aug 2026
Trial completion • Trial primary completion date • Atopic Dermatitis • Dermatology • Immunology • Vitiligo • ABCA1 • KRT1 • KRT5
|